Sobrera

Sobrera Pharma

This pharmaceutical company develops medical treatments for patients suffering from alcohol use disorder and other addiction-related conditions.

Amygdala Neurosciences

This biopharmaceutical company develops oral enzyme inhibitors to treat substance use disorders by reducing cravings and preventing relapse in patients.

Enabling psychedelics-assisted therapies

This biopharmaceutical company develops psychedelic-inspired medicines and a care delivery model to treat addiction for patients and healthcare providers.

Newleos Therapeutics

The company develops oral small-molecule drugs to treat neuropsychiatric disorders, including anxiety and substance use disorders, for patients seeking therapies with fewer side effects.

Syremis

This biopharmaceutical company develops oral small-molecule medicines for patients with schizophrenia, major depressive disorder, and other serious mental health conditions.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.

Monument Therapeutics

This biotech company develops digital biomarkers and targeted drugs to treat patients with schizophrenia and other neurological conditions.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.